- IsoRay (ISR) shares jump 12.9% after the company says that its Cesium-131 seeds have been inserted into a human prostate for the first time.
- Steven Frank of the Anderson Cancer Center, who performed the implant, said that with its short half-life, Cesium-131 "offers rapid resolution of the acute side effects that can be associated with prostate treatment with brachytherapy".
- IsoRay's technology enables doctors to directly place radiation in areas where cancer is most likely to remain after a tumor is removed. (PR)
IsoRay seeds implanted into human prostate for first time; shares spike
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs